Bristol-Myers Squibb Company (BMY)

48.96
1.00 2.10
NYSE : Health Care
Prev Close 50.00
Open 50.10
Day Low/High 48.93 / 50.14
52 Wk Low/High 48.92 / 77.12
Volume 17.16M
Avg Volume 11.19M
Exchange NYSE
Shares Outstanding 1.67B
Market Cap 82.27B
EPS 0.90
P/E Ratio 15.98
Div & Yield 1.56 (3.20%)

Latest News

Is It Time to Buy Beaten-Down Bristol-Myers Squibb Stock?

Is It Time to Buy Beaten-Down Bristol-Myers Squibb Stock?

Bristol-Myers Squibb stock has fallen by 35% in the last six months.

Allergan, Apple, Facebook: Doug Kass' Views

Allergan, Apple, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on buying retail, and discusses why he's favoring the short side in a big way.

Bristol-Myers Squibb, Merck, Synergy Pharmaceuticals: Doug Kass' Views

Bristol-Myers Squibb, Merck, Synergy Pharmaceuticals: Doug Kass' Views

Doug Kass shares his thoughts on biotech and discusses the shape of things to come.

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The weak companies could be clobbered.

Buy 'Trump Stocks' on Any Market-Induced Weakness: Cramer's 'Mad Money' Recap (Friday 1/20/17)

Buy 'Trump Stocks' on Any Market-Induced Weakness: Cramer's 'Mad Money' Recap (Friday 1/20/17)

The idea of buying American and hiring American is good news for defense, ag and energy stocks, says Jim Cramer.

Jim Cramer on Bristol-Myers' Opdivo/Yervoy Combo: 'That Story Was Taken Away From Us'

Jim Cramer on Bristol-Myers' Opdivo/Yervoy Combo: 'That Story Was Taken Away From Us'

Bristol-Myers has had a mostly negative narrative since October, TheStreet's Jim Cramer said.

Bristol-Myers Squibb And Ono Pharmaceutical Company Enter Settlement And License Agreement With Merck To Resolve PD-1 Antibody Patent Litigation

Bristol-Myers Squibb And Ono Pharmaceutical Company Enter Settlement And License Agreement With Merck To Resolve PD-1 Antibody Patent Litigation

Bristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical Company, Ltd.

Stocks Rising as Donald Trump Inherits the White House

Stocks Rising as Donald Trump Inherits the White House

Stocks are higher on Friday after Donald Trump is sworn in as the 45th president of the United States.

Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know

Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know

Here's how to trade seven of the most active stocks on the market this week.

Jim Cramer Shares His Concerns About Bristol-Myers Squibb

Jim Cramer Shares His Concerns About Bristol-Myers Squibb

Jim Cramer looks at Bristol-Myers Squibb's Opdivo setback.

Stocks Come Off Highs as Trump Pledges to Rebuild America

Stocks Come Off Highs as Trump Pledges to Rebuild America

Stocks pare gains on Friday as Donald Trump is sworn in as 45th President of the United States.

Stock Futures Rise but in Hesitant Trading as Trump Prepares to Take Office

Stock Futures Rise but in Hesitant Trading as Trump Prepares to Take Office

Stock futures creep higher on Friday in hesitant trading ahead of the inauguration of President-elect Donald Trump.

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.

Bristol-Myers Squibb Provides Regulatory Update In First-line Lung Cancer

Bristol-Myers Squibb Provides Regulatory Update In First-line Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has decided not to pursue an accelerated regulatory pathway for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.

Opdivo (nivolumab) Demonstrated Efficacy And Improved Survival In Patients With Previously Treated Advanced Gastric Cancer In A Randomized Phase 3 Study

Opdivo (nivolumab) Demonstrated Efficacy And Improved Survival In Patients With Previously Treated Advanced Gastric Cancer In A Randomized Phase 3 Study

Bristol-Myers Squibb Company (NYSE:BMY) announced today the results of ONO-4538-12 demonstrating Opdivo (nivolumab) significantly reduced the risk of death by 37% (HR 0.

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

Jana Partners' Barry Rosenstein recently acquired a large stake in Bristol-Myers.

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.

Bristol-Myers and AstraZeneca Take Beatings

Bristol-Myers and AstraZeneca Take Beatings

It happened in the wake of Merck's latest drug approval.

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Bristol-Myers Squibb And GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration

Bristol-Myers Squibb And GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration

Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc.

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Congressional Republicans who scrapped plans to overhaul the Office of Congressional Ethics might be regretting their decision. Senate Dems are asking for an investigation into HHS pick Tom Price.

Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration With Janssen To Evaluate Opdivo (nivolumab) In Combination With Darzalex (daratumumab)

Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration With Janssen To Evaluate Opdivo (nivolumab) In Combination With Darzalex (daratumumab)

Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.